CRS
Carpenter Technology Corporation
CRS has the edge over RKLB overall, supported by lower modeled downside and stronger valuation.
RKLB
Rocket Lab USA, Inc.
RKLB's outlook is improving, though it still trails on the overall score.
CRS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Healthy |
CRS's revenue, profitability, cash flow and balance sheet are all currently healthy.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CRS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $222 | -26% |
| Forward | 22x | $300 | — |
| Current | 26x | $300 | — |
| Fair | 38x | $427 | +43% |
| Expensive | 50x | $572 | +91% |
Historical ranges are pointers, not guarantees.
CRS's PE is in its cheap range at 26x. If earnings grow as analysts expect, today's price would be 22x next year's earnings.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
CRS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CRS, with profitability improving.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.93 | +23% |
| Q3 2026 | $11.34 | +39% |
| Q2 2026 | $10.52 | +42% |
| Q1 2026 | $9.50 | +35% |
| Q4 2025 | $8.61 | +62% |
| Q3 2025 | $8.18 | +82% |
| Q2 2025 | $7.42 | +101% |
| Q1 2025 | $7.06 | +169% |
| Q4 2024 | $5.30 | +84% |
CRS has the edge over RKLB on earnings quality, reporting a profit while its opponent remains loss making.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
CRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $798.2M | +8.8% |
| Q2 2026 | $851M | +13% |
| Q1 2026 | $811.5M | +12% |
| Q4 2025 | $728M | +7.5% |
| Q3 2025 | $733.7M | +2.2% |
| Q2 2025 | $755.6M | -5.4% |
| Q1 2025 | $727M | +6.1% |
| Q4 2024 | $676.9M | +8.4% |
CRS's revenue is recovering but still below its 2023 peak: $798M last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | +3.7 points |
| Q2 2026 | 24% | +4.3 points |
| Q1 2026 | 23% | +4 points |
| Q4 2025 | 21% | +3.8 points |
| Q3 2025 | 21% | +5.1 points |
| Q2 2025 | 20% | +6.5 points |
| Q1 2025 | 19% | +7.9 points |
| Q4 2024 | 18% | +6.4 points |
CRS has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over CRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
CRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.9M | -$21.5M |
| Q2 2026 | $155M | -23% |
| Q1 2026 | $124.8M | +267% |
| Q4 2025 | $85.9M | +123% |
| Q3 2025 | -$3.4M | -126% |
| Q2 2025 | $200.1M | +41% |
| Q1 2025 | $34M | -45% |
| Q4 2024 | $38.6M | +$49.4M |
CRS has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
CRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -200K shares |
| 1 year | -0.8% | -400K shares |
| 3 years | +0.2% | +100K shares |
| 5 years | +3.1% | +1.5M shares |
| Available history | +3.1% | +1.5M shares |
CRS has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $133.9M |
| Q2 2026 | $45.2M |
| Q1 2026 | $52.7M |
| Q4 2025 | $32.1M |
| Q3 2025 | $49.1M |
| Q2 2025 | $24.1M |
| Q1 2025 | $37.5M |
| Q4 2024 | $8.2M |
CRS spent $264M buying back its own shares over the past year, up 122% from the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.0x | Very low |
CRS's net debt is less than a year of its operating earnings (EBITDA).
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.0 | Neutral |
| Stochastic | 4.9 | Oversold |
CRS's weekly RSI is 32 (neutral) and its Stochastic is 5 (oversold).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
CRS PE vs Industrials Sector
| Metric | CRS | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 24x | 9.8% above |
| PE % | 22 | 58 | 36 pts below |
CRS is trading at 26x earnings, in line with the Industrials sector's median of 24x.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
CRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.7 | 11% below |
| 20 week MA | $448.1 | 33% below |
| 50 week MA | $420.4 | 29% below |
| 100 week MA | $326.6 | 8.3% below |
| 200 week MA | $206.4 | 45% above |
CRS has fallen below most of its moving averages, though it's still 45% above its 200-week average.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB has the edge over CRS on trend strength, trading above more of its moving averages.
CRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.3 | $28.6 | -43% |
| 2021 | $28.6 | $29.0 | +1.2% |
| 2022 | $29.0 | $37.8 | +30% |
| 2023 | $37.8 | $70.8 | +87% |
| 2024 | $70.8 | $170.7 | +141% |
| 2025 | $170.7 | $334.4 | +96% |
| 2026 YTD | $334.4 | $299.6 | -10% |
CRS's yearly returns have swung widely, from +141% in 2024 to −43% in 2020. It's down 10% so far in 2026.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over CRS on returns for 2026, with the stronger performance.